Targeting Oncogenic RAS With Tri-Complex RAS(ON) Inhibitors
- New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors
- Exploring strategic combination approaches to amplify efficacy and expand therapeutic reach, building on emerging insights across RAS driven tumor biology
- Showcasing a major year of clinical progress in the field